Summary
This Form 8-K filing by Gilead Sciences, Inc. (GILD) on August 7, 2018, primarily details the separation agreement for its outgoing President and CEO, John F. Milligan, Ph.D. The agreement outlines the terms of his departure, including his continued service through February 28, 2019, to assist with transitional matters. Investors should note the compensation and benefits provided to Dr. Milligan as part of this separation, which include pro-rated and accelerated vesting of equity awards, a guaranteed bonus for 2019, severance pay, and healthcare continuation support. The filing also signifies the formalization of the previously announced CEO transition. While the specific details of the successor are not in this report, the primary focus is on the financial and contractual arrangements governing Dr. Milligan's exit and transition period. This information is crucial for understanding potential impacts on executive compensation disclosures and the company's commitment to an orderly leadership change.
Key Highlights
- 1Gilead Sciences formalized the separation agreement with its President and CEO, John F. Milligan, Ph.D., effective August 6, 2018.
- 2Dr. Milligan will continue to serve through December 31, 2018, or until a successor is appointed, and will remain an employee for transitional matters until February 28, 2019.
- 3The separation agreement includes payment of Dr. Milligan's 2018 bonus based on actual corporate performance.
- 4Subject to transition services, Dr. Milligan will receive a $1.5 million bonus for 2019.
- 5The agreement provides for accelerated vesting of Dr. Milligan's unvested stock options and full settlement of performance share awards.
- 6Dr. Milligan will receive severance equivalent to two times his salary plus average annual bonus over the past three years.
- 7The company will partially offset healthcare continuation costs for two years and provide one year of outplacement services.